302 related articles for article (PubMed ID: 29775292)
41. Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
Song H; Niu X; Quan J; Li Y; Yuan L; Wang J; Ma C; Ma E
Bioorg Chem; 2020 Apr; 97():103679. PubMed ID: 32120077
[TBL] [Abstract][Full Text] [Related]
42. Mechanistic and Structural Insights on Difluoromethyl-1,3,4-oxadiazole Inhibitors of HDAC6.
Cellupica E; Gaiassi A; Rocchio I; Rovelli G; Pomarico R; Sandrone G; Caprini G; Cordella P; Cukier C; Fossati G; Marchini M; Bebel A; Airoldi C; Palmioli A; Stevenazzi A; Steinkühler C; Vergani B
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892072
[TBL] [Abstract][Full Text] [Related]
43. Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6.
Sixto-López Y; Bello M; Correa-Basurto J
J Biomol Struct Dyn; 2019 Nov; 37(18):4701-4720. PubMed ID: 30558483
[TBL] [Abstract][Full Text] [Related]
44. Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6.
Vanaja GR; Ramulu HG; Kalle AM
Cell Commun Signal; 2018 May; 16(1):20. PubMed ID: 29716651
[TBL] [Abstract][Full Text] [Related]
45. Design, Synthesis, Bioactivity Evaluation, Crystal Structures, and In Silico Studies of New α-Amino Amide Derivatives as Potential Histone Deacetylase 6 Inhibitors.
Xu Y; Tang H; Xu Y; Guo J; Zhao X; Meng Q; Xiao J
Molecules; 2022 May; 27(10):. PubMed ID: 35630812
[TBL] [Abstract][Full Text] [Related]
46. Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studies.
Uba AI; Yelekçi K
Comput Biol Chem; 2018 Aug; 75():131-142. PubMed ID: 29859380
[TBL] [Abstract][Full Text] [Related]
47. A novel class of anthraquinone-based HDAC6 inhibitors.
Song Y; Lim J; Seo YH
Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327
[TBL] [Abstract][Full Text] [Related]
48. Rational design of selective HDAC2 inhibitors for liver cancer treatment: computational insights into the selectivity mechanism through molecular dynamics simulations and QM/MM calculations.
Yang Y; Hu B; Yang Y; Gong K; Wang H; Guo Q; Tang X; Li Y; Wang J
Phys Chem Chem Phys; 2021 Aug; 23(32):17576-17590. PubMed ID: 34369509
[TBL] [Abstract][Full Text] [Related]
49. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition.
Miyake Y; Keusch JJ; Wang L; Saito M; Hess D; Wang X; Melancon BJ; Helquist P; Gut H; Matthias P
Nat Chem Biol; 2016 Sep; 12(9):748-54. PubMed ID: 27454931
[TBL] [Abstract][Full Text] [Related]
50. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
Cosenza M; Pozzi S
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30096875
[TBL] [Abstract][Full Text] [Related]
51. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
52. Histone deacetylase 6 structure and molecular basis of catalysis and inhibition.
Hai Y; Christianson DW
Nat Chem Biol; 2016 Sep; 12(9):741-7. PubMed ID: 27454933
[TBL] [Abstract][Full Text] [Related]
53. Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
Wagner FF; Olson DE; Gale JP; Kaya T; Weïwer M; Aidoud N; Thomas M; Davoine EL; Lemercier BC; Zhang YL; Holson EB
J Med Chem; 2013 Feb; 56(4):1772-6. PubMed ID: 23368884
[TBL] [Abstract][Full Text] [Related]
54. A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors.
Goracci L; Deschamps N; Randazzo GM; Petit C; Dos Santos Passos C; Carrupt PA; Simões-Pires C; Nurisso A
Sci Rep; 2016 Jul; 6():29086. PubMed ID: 27404291
[TBL] [Abstract][Full Text] [Related]
55. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
Vannini A; Volpari C; Filocamo G; Casavola EC; Brunetti M; Renzoni D; Chakravarty P; Paolini C; De Francesco R; Gallinari P; Steinkühler C; Di Marco S
Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15064-9. PubMed ID: 15477595
[TBL] [Abstract][Full Text] [Related]
56. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.
Krennhrubec K; Marshall BL; Hedglin M; Verdin E; Ulrich SM
Bioorg Med Chem Lett; 2007 May; 17(10):2874-8. PubMed ID: 17346959
[TBL] [Abstract][Full Text] [Related]
57. Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors.
Dowling DP; Gantt SL; Gattis SG; Fierke CA; Christianson DW
Biochemistry; 2008 Dec; 47(51):13554-63. PubMed ID: 19053282
[TBL] [Abstract][Full Text] [Related]
58. Development and Validation of High-Content Analysis for Screening HDAC6-Selective Inhibitors.
Nong Y; Hou Y; Pu Y; Li S; Lan Y
SLAS Discov; 2021 Jun; 26(5):628-641. PubMed ID: 33783263
[TBL] [Abstract][Full Text] [Related]
59. Structure, Functions and Selective Inhibitors of HDAC6.
Liang T; Fang H
Curr Top Med Chem; 2018; 18(28):2429-2447. PubMed ID: 30499393
[TBL] [Abstract][Full Text] [Related]
60. Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction.
Sharma C; Oh YJ; Park B; Lee S; Jeong CH; Lee S; Seo JH; Seo YH
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]